Mammography Systems Market By Product (Full-Field Digital Mammography Systems, Digital Breast Tomosynthesis Systems, Contrast-Enhanced Mammography Systems, Other Mammography Systems), By Application (Breast Cancer Screening, Diagnostic Assessment, Biopsy Guidance and Treatment Planning), By End User (Hospitals, Diagnostic Imaging Centers, Breast Care Centers, Specialty Clinics, Mobile Screening Units), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Mammography Systems Market: Screening Expansion, 3D Upgrades, and the Shift Toward Integrated Breast Imaging

The Global Mammography Systems Market was valued at USD 2.90 billion in 2025 and is projected to reach USD 4.91 billion by 2032, expanding at a CAGR of 7.8% during 2026–2032, according to Strategic Market Research.

 

Mammography systems are low-dose X-ray platforms used for breast cancer screening and diagnostic assessment. Their commercial value extends well beyond the initial equipment sale, as every installed system generates ongoing demand for detectors, workstations, software, maintenance contracts, quality-control services, image storage, staff training, biopsy procedures, and periodic upgrades.

 

Market growth is driven by broader screening adoption, ongoing technology upgrades, and greater reliance on advanced imaging software. Purchasing is therefore shifting from standalone imaging equipment toward integrated breast-imaging environments that combine screening, diagnostic assessment, biopsy guidance, workflow management, data storage, and long-term service support.

 

Screening Volumes Create a Durable Equipment and Service Base

The United States remains the most developed commercial market for mammography systems. FDA data from July 2026 recorded 9,107 certified facilities, 27,622 accredited units, and approximately 44.78 million annual mammography procedures. Federal inspections covered 6,467 facilities and 19,333 units. Around 83.4% of inspections identified no noncompliance, while 1.0% reported Level 1 findings and 15.6% reported Level 2 findings. The scale of these inspections highlights the recurring need for quality assurance, equipment servicing, compliance support, and staff training across the installed base.

Demand may strengthen further as screening eligibility expands. The U.S. Preventive Services Task Force recommends mammography every two years for women aged 40 to 74, replacing its earlier position that women in their forties should make individual screening decisions. Both digital mammography and digital breast tomosynthesis are recognised as effective primary screening methods.

Screening participation remains high but uneven. In 2023, 80.0% of U.S. women aged 50 to 74 had received a mammogram within the previous two years, compared with 62.1% of women aged 40 to 49. Among women aged 50 to 74, state-level participation ranged from 64.0% to 85.5%, showing that equipment availability alone does not overcome barriers such as insurance coverage, transportation, scheduling, and access to regular healthcare providers.

 

FFDM Protects the Installed Base While 3D Systems Capture Upgrade Spending

Full-field digital mammography, or FFDM, remains the foundation of breast-screening infrastructure. Digital detectors replace film, reducing physical storage requirements and allowing images to be transferred easily between radiologists and healthcare facilities.

FDA data recorded 14,147 accredited 2D digital units across 9,106 U.S. facilities in July 2026. These systems represented approximately 51.2% of the country’s accredited mammography equipment base. FFDM therefore remained slightly ahead of tomosynthesis by installed unit count and continued to serve public screening programs, smaller hospitals, mobile services, and facilities unable to justify immediate investment in higher-priced platforms.

New equipment demand, however, is increasingly moving toward digital breast tomosynthesis. DBT captures images from several angles and produces layered views of breast tissue, reducing the likelihood that abnormalities will be hidden by overlapping tissue. By July 2026, 8,623 U.S. facilities, or approximately 94.7% of certified sites, had DBT capability, supported by 13,475 accredited 3D units.

DBT accounted for approximately 48.8% of accredited mammography equipment, compared with 47.8% in August 2024. Accredited 3D capacity increased by about 8.3% between August 2024 and July 2026, while the number of 2D units rose by approximately 4.0%. This difference indicates that installation and replacement activity is gradually shifting the equipment mix toward tomosynthesis.

FDA approvals reinforce the commercial position of the leading 3D mammography suppliers. Hologic’s Selenia Dimensions 3D System is approved under P080003 for 2D and 3D screening and diagnostic assessment. The original decision was issued on February 11, 2011, and the approval family currently includes 10 supplements covering subsequent system, software, labelling, and imaging updates.

Siemens’ Mammomat Inspiration with Tomosynthesis Option is approved under P140011. The original PMA decision was issued on April 21, 2015, and the approval family includes eight supplements involving later developments such as the Mammomat Revelation and Mammomat B.brilliant product lines. Supplement P140011/S007 expanded approved screening options in 2020, while P140011/S009 received an FDA decision on July 1, 2026.

GE HealthCare’s Senographe Pristina 3D is covered under P130020/S002, approved on March 3, 2017, for 3D breast screening and diagnostic imaging. The wider P130020 family includes five supplements. The latest listed update, P130020/S005, was approved on November 21, 2025, and introduced a revised image-processing approach for the Pristina 3D system.

Together, the Hologic, Siemens, and GE approval families contain 23 listed FDA PMA supplements. This activity shows that competition continues well beyond initial product approval. Manufacturers use supplemental approvals to update software, expand imaging and diagnostic capabilities, revise manufacturing arrangements, and extend established hospital relationships.

Clinical evidence also supports continued upgrades, although results vary by patient group and screening environment. A 10-year study covering 272,938 examinations found that DBT detected more cancers and reduced the proportion diagnosed at an advanced stage compared with conventional digital mammography. USPSTF modelling estimated that DBT could also produce 167 fewer false-positive findings per 1,000 people screened, although the benefit may be less pronounced among women with extremely dense breasts.

For healthcare providers, fewer recalls can reduce repeat examinations, follow-up appointments, and pressure on diagnostic services. Higher detection of invasive cancers can also support earlier referrals into biopsy and oncology pathways. These operational and clinical benefits make DBT commercially attractive to high-volume facilities despite its higher acquisition cost.

FFDM will remain commercially relevant through replacement sales, detector upgrades, maintenance contracts, and mobile-screening programs. DBT, however, is positioned to generate stronger new-system revenue as hospitals increasingly assess mammography platforms based on diagnostic performance, examination time, interpretation workload, and the ability to add biopsy or contrast-enhanced imaging functions.

 

Contrast-Enhanced Mammography Expands the Diagnostic Revenue Pool

Contrast-enhanced mammography is emerging as a higher-value diagnostic segment rather than a replacement for routine population screening. The technique combines digital mammography with an iodine-based contrast agent, helping suspicious areas appear more clearly when initial screening results are uncertain.

CEM is used to investigate abnormal screening findings, assess the extent of newly diagnosed cancer, clarify inconclusive results, monitor treatment response, and evaluate selected high-risk patients. Evidence reviewed by the Society of Breast Imaging indicates that CEM can deliver results comparable with contrast-enhanced breast MRI in suitable clinical settings.

Its commercial potential is strongest where MRI capacity is limited, waiting times are long, or providers want to expand diagnostic services through an existing mammography platform. Adoption remains more selective than DBT because CEM requires contrast administration, patient eligibility checks, trained personnel, reimbursement support, and established clinical protocols.

Product development is bringing CEM closer to biopsy and treatment-planning workflows. On June 30, 2026, Siemens Healthineers announced FDA clearance for contrast-enhanced mammography and contrast-enhanced biopsy on the Mammomat B.brilliant platform. Building on its earlier tomosynthesis approvals, the clearance allows providers to investigate suitable suspicious findings within the mammography pathway rather than transferring every patient to a separate MRI-guided procedure.

The Siemens clearance and GE’s November 2025 Pristina 3D update indicate that manufacturers are expanding the capabilities of established systems rather than replacing entire product families. This strategy shortens the commercial pathway and allows hospitals to add diagnostic imaging, biopsy, and software functions to equipment already in use.

 

Breast-Density Rules Reshape Diagnostic Follow-Up

The amended U.S. Mammography Quality Standards Act regulations became enforceable in September 2024, requiring mammography facilities to include standardised breast-density information in patient notifications and clinical reports.

The regulation does not require automatic follow-up testing, but it encourages greater discussion between patients and clinicians about the reduced sensitivity of conventional mammography in dense breast tissue. As a result, providers may reassess their access to DBT, ultrasound, MRI, and contrast-enhanced mammography when planning diagnostic capacity.

The commercial impact will vary across imaging modalities. The USPSTF continues to find insufficient evidence to recommend routine supplemental ultrasound or MRI after a negative mammogram in women with dense breasts. Equipment and service demand will therefore depend on patient demographics, reimbursement, specialist availability, facility capacity, and local clinical guidelines rather than breast-density reporting alone.

 

Software and Workforce Pressures Change the Buyer’s Priorities

Interpretation capacity is becoming as important as equipment capacity. The 2025 American Society of Radiologic Technologists staffing survey estimated an 11.4% vacancy rate in mammography, compared with 5.6% in 2019. The average number of budgeted mammography positions per responding department also decreased from 5.2 in 2023 to 4.8 in 2025.

Facilities facing staff shortages place greater value on systems that reduce positioning delays, shorten image-processing time, retrieve prior examinations, simplify quality checks, and direct radiologists toward cases requiring closer review. Software that produces measurable workflow improvements may consequently generate more purchasing interest than minor hardware improvements.

GE HealthCare introduced the Pristina Via platform in 2025 alongside U.S. distribution of DeepHealth’s SmartMammo software. The offering reflects competition around faster examination workflows, comparison with prior images, AI-supported review, and patient experience rather than detector specifications alone.

FDA clearances for ScreenPoint Medical’s Transpara and VinBigData’s VinDr-Mammo also show that software companies are entering the breast imaging workflow through computer-aided detection, diagnosis, and case-prioritization tools. These applications can be sold alongside equipment or added to existing digital fleets, widening the addressable market beyond new system installations.

 

Competitive Positioning Shifts Toward Recurring Revenue

Hologic, GE HealthCare, Siemens Healthineers, Fujifilm, Canon Medical Systems, and other imaging companies compete across digital mammography, tomosynthesis, biopsy systems, software, and service support. Competitive strength increasingly depends on portfolio breadth and the ability to retain facilities through upgrades, maintenance, and workflow integration after installation.

Hologic’s Breast Health segment generated USD 1.484 billion in fiscal 2025, down 2.5% from USD 1.523 billion in fiscal 2024. Product revenue reached USD 829.5 million, accounting for approximately 55.9% of segment revenue, but declined 9.1% as digital mammography systems, including 3D Dimensions platforms and related workstations, faced longer sales cycles.

Based on reported segment and product revenue, service and other activities contributed an estimated USD 654.6 million, or 44.1% of Breast Health revenue, in fiscal 2025. Hologic also reported an 8.9% increase in overall service and other revenue, partly supported by service contracts linked to its expanding digital mammography installed base. The segment therefore recorded weaker equipment sales alongside stronger recurring service revenue.

 

Regional Demand Reflects Different Screening Models

North America remains the leading regional market because of its large installed base, high screening participation, DBT penetration, Medicare coverage, state insurance requirements, and structured FDA quality controls. The United States alone accounted for 27,622 accredited units and more than 44.7 million reported annual procedures in July 2026. Growth will come mainly from replacement, software adoption, CEM expansion, workflow upgrades, and continued conversion of older 2D capacity.

Europe is shaped by centrally funded screening programs and country-specific procurement cycles. England reported 6.67 million eligible women and 71.8% breast-screening coverage in 2025. During 2024–2025, 73,451 women were referred for diagnostic assessment and 19,291 cancers were detected, of which 79.5% were invasive.

Public investment continues to support both fixed and mobile mammography capacity. The UK government previously allocated £10 million for 29 additional breast-screening units, including 16 mobile and 13 fixed systems, alongside nearly 70 software and service upgrades.

Asia-Pacific combines mature national programs with substantial access gaps. BreastScreen Australia recorded more than 1.9 million participants in 2022–2023, equal to 52% of women aged 50–74. Among program-detected cancers in 2023, 58% were 15 millimetres or smaller.

 

Market Outlook

The Mammography Systems Market will develop through three connected revenue streams: replacement of established FFDM fleets, conversion to DBT and integrated biopsy systems, and expansion of software and service revenue around the installed base.

DBT is likely to remain the principal growth technology, while FFDM continues to support large screening volumes and cost-sensitive programs. CEM will expand more gradually through diagnostic centres, tertiary hospitals, dense-breast pathways, and facilities seeking an alternative to breast MRI for selected patients.

Workforce availability may become a stronger constraint than system supply. Buyers will increasingly favour platforms that reduce examination delays, support prior-image comparison, simplify quality control, and allow software upgrades without replacing the entire system.

 

Mammography Systems Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.90 Billion
Revenue Forecast in 2032	USD 4.91 Billion
Overall Growth Rate	CAGR of 7.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Full-Field Digital Mammography Systems, Digital Breast Tomosynthesis Systems, Contrast-Enhanced Mammography Systems, Other Mammography Systems
By Application	Breast Cancer Screening, Diagnostic Assessment, Biopsy Guidance and Treatment Planning
By End User	Hospitals, Diagnostic Imaging Centers, Breast Care Centers, Specialty Clinics, Mobile Screening Units
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Expansion of organized breast cancer screening programs, replacement of aging FFDM fleets, rising adoption of digital breast tomosynthesis, growth in breast-density-led diagnostic follow-up, wider use of AI-supported interpretation and workflow tools, and increasing demand for integrated biopsy and contrast-enhanced imaging capabilities
Customization Option	Available upon request